NASDAQ · CMRX
Chimerix, Inc.
$8.54$0.00 (0.0%)
Chimerix, Inc.’s quoted price sits in the upper half of its reported 52-week range, 0.12% below the high.
Loading market information…
NASDAQ · IKNA · USD
Stock price, earnings
Quote as of Jul 25, 2025, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Ikena Oncology, Inc.’s quoted price sits in the upper half of its reported 52-week range, 26.29% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Upcoming dates and analyst estimates may change. Fiscal quarters follow Ikena Oncology, Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Ikena Oncology, Inc. is a biopharmaceutical company specializing in precision oncology. Its primary objective is to create therapeutic agents specifically formulated for patient populations identified through biomarkers, thereby addressing significant unmet medical needs. The company's leading drug candidate is IK-930, an orally administered small molecule designed to inhibit the transcriptional enhanced associate domain (TEAD) transcription factor, a key component of the Hippo signaling pathway. Ikena is also progressing a portfolio of other investigational therapies, including: A small molecule inhibitor program targeting ERK5 within the RAS signaling pathway. IK-175, an oral compound that inhibits the aryl hydrocarbon receptor. IK-007, an orally delivered, selective antagonist of the EP4 receptor, which is being developed for the treatment of microsatellite stable colorectal cancer. Founded in 2016, the company is based in Boston, Massachusetts.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 02:49 PM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| Q4 2023 | Mar 12, 2024 | -$0.410.0% vs estimate | $659.00K-79.01% vs estimate |
|---|
THE ANALYST VIEW
5 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
Percentages compare targets with the quoted price when currencies match. Targets are analyst estimates, not guaranteed outcomes.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$8.54$0.00 (0.0%)
Chimerix, Inc.’s quoted price sits in the upper half of its reported 52-week range, 0.12% below the high.
$12.49$0.00 (0.0%)
Avid Bioservices, Inc.’s quoted price sits in the upper half of its reported 52-week range, 0.16% below the high.
$19.00+$0.04 (+0.21%)
Intercept Pharmaceuticals, Inc.’s quoted price sits in the upper half of its reported 52-week range, 13.08% below the high.
$0.60-$0.10 (-14.27%)
ASLAN Pharmaceuticals Limited’s quoted price sits in the lower half of its reported 52-week range, 96.48% below the high.
$15.31-$0.14 (-0.91%)
Icosavax, Inc.’s quoted price sits in the upper half of its reported 52-week range, 4.94% below the high.
$4.84$0.00 (0.0%)
Exscientia plc: Healthcare · Biotechnology.
$8.68$0.00 (0.0%)
Sage Therapeutics, Inc.’s quoted price sits in the upper half of its reported 52-week range, 7.26% below the high.
$10.15+$0.02 (+0.2%)
iTeos Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 42.43% below the high.
